Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosohamide and ifosfamide)

Experimental and Clinical Endocrinology and Diabetes

Volumn 107, Issue 3, 1999, Pages 177-182

  Reinhardt, Walter ^a,e   Sauter, V ^a   Jockenhovel F ^f   Kummer, G ^d   Uppenkamp, M ^b   Witzke, O ^c   Philipp, T ^c   Reinwein, D ^a   Mann, K ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Div of Hematology   (Germany)

^c Div of Nephrology   (Germany)

^d Clinic Bone Marrow Transplantation   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f NONE

Author keywords

Alkylating drugs; Cyclophosphamide; Ifosfamide; Thyroid function; Thyroid hormones

Indexed keywords

3,3',5' TRIIODOTHYRONINE; ALBUMIN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; LIOTHYRONINE; MESNA; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; PREALBUMIN; PREDNISONE; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FREE THYROXINE INDEX; HEMORRHAGIC CYSTITIS; HORMONE RELEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIOTHYRONINE BLOOD LEVEL; LIVER; LYMPHOMA; PRIORITY JOURNAL; RELAPSE; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; VOMITING; WEGENER GRANULOMATOSIS;

EID: 0033007096     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1212094     Document Type: Article

References (21)

1. Brabant A, Brabant G, Schuermeyer T, Ranft U, Schmidt FW, Hesch RD, Von zur Mühlen A: The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol 121: 95-100, 1989
2. Brock N, Stekar J.: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittelforsch (Drug Research): 29, 659-661, 1979
3. Bruckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB.: High-dose cyclophosphamide therapy for malignant disease: toxicitiy, tumor response, and the effects of stored autologous marrow. Cancer 29: 357-365, 1972
4. Bürgi H, Wimpfheimer C, Burger A, Zaunbauer W, Rösler H, Lemarchand-Beraud T: Changes of circulation thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents. J Clin Endocrinol Metab 43: 1203-1209, 1976
5. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ: IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693-697, 1982
6. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH: Opposite effects of dexamethasone on serum concentrations of 3,3'5'-triiodothyronine (reverse T3) and 3,3'5'-triiodothyronine (T3) J Clin Endocrinol Metab 41: 911-920, 1975
7. Felicetta JV, Green WL, Nelp WB: Inhibition of hepatic binding of thyroxine by cholecystographic agents. J Clin Invest 65: 1032-1040, 1980
8. Fraiser HL, Kanekal S, Kehrer JP: Cyclophophamide toxicity. Drugs 42: 781-795, 1991
9. Hoffmann GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498, 1992
10. Hoffmann GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J of Med 89: 403-410, 1990
11. Mendel KM, Frost PH, Kunitake ST, Cavalieri RR: Mechanism of the heparin-induced increase in the concentration of free thyroxin in plasma. J Clin Endocrinol Metab 65: 1259-1264, 1987
12. Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 20: 194-208, 1991
13. Oppenheimer JH, Werner SC: Effect of prednisolone on thyroxine binding proteins. J Clin Endocrinol Metab 26: 715-721, 1966
14. Pohl J, Brock N.: The development of mesna for regional detoxification. Cancer treatm rev: 10 supp A 33-43, 1982
15. Re RN, Kourides IA, Ridgway EC, Weintraub BD, Maloof F: The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab 43: 338-346, 1976
16. Steppat D, Gross WL: Stage adapted treatment of Wegener's granulomatosis. Klin Wochenschrift 67: 666-672, 1989
17. Surks MI, Sievert R: Drugs and thyroid function. N Engl J Med 21: 1688-1694, 1995
18. Suzuki H, Kadena N, Takeuchi K, Nakagawa S: Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-thyroid axis. Acta Endocrinol 92: 477-488, 1979
19. Suzuki H, Noguchi K, Nakahata M, Nakagawa S, Kadena N: Effect of iopanoic acid on the pituitary-thyroid axis: time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones. J Clin Endocrinol Metab 53: 779-783, 1981
20. Unger J, van Heuverswijn B, Decoster C, Cantraine F, Mockel J, van Herle AJ: Thyroglobulin and thyroid hormone release after intravenous administration of bovine thyrotropin in man. J Clin Endocrinol Metab 51: 590-596, 1980
21. Zalupski M, Baker LH: Ifosfamide. J Nat Canc Inst 80: 556-566, 1988